Clinigen Clinical Trials Supply (Clinigen CTS) has entered an exclusive clinical trial distribution agreement with Accord Healthcare, the wholly-owned marketing subsidiary of India’s Intas Pharmaceuticals, covering the administration and distribution of Accord’s injectable cancer drugs across the EU.
Clinigen CTS will act as the sole point of enquiry, order receipt and distribution of Accord products to manufacturers, CROs, clinical trial contract packagers and other specialist service providers looking to source pharmaceutical products for use in clinical trials in the EU. Accord markets more than 15 generic injectable cancer drugs in the EU including carboplatin, docetaxel, irinotecan and oxaliplatin and has more than 50 injectable molecules in development or registration.
James Burt, vice president Hospitals at Accord Healthcare, commented, “We consider timely fulfillment of requests as being of utmost importance and as demand for our products has grown, we decided that outsourcing distribution activities to a specialist in the clinical trial supply space made sense both for Accord and for our customers. A critical consideration for us in choosing a partner was the fact that Clinigen CTS only sources products for clinical trials and tracks them all the way from source to the point of use. This reassured us that no Accord products will be diverted through other channels for alternative purposes.”
Shaun Chilton, chief operating officer of Clinigen’s Services division, added, “Accord’s rapid expansion to having a presence in many global territories underlines its impressive growth. As an innovative, forward-thinking company, their culture very much mirrors that of Clinigen. Even before our new agreement with Accord, we have been receiving frequent requests for injectable cancer products. We are now able to connect the manufacturing capacity of Intas with our own European distribution network which gives us confidence that this will be an excellent working relationship on both sides.”